[Wavefront analysis in pseudophakic eyes by using allegretto wave analyzer].
OBJECTIVE
To analyze the wavefront aberrations of pseudophakic eyes.


METHODS
Seventy-eight patients (84 eyes) who have undergone phacoemulsification and Alcon Acrysof SA60AT intraocular lens were divided into 3 groups by the stage of post-operation. Allegretto Wave Analyzer (Wavelight Laser Technologie AG, Germany) implanted into the eyes was applied to analyze the wavefront aberrations. Twenty-three healthy normal eyes were involved in the control group.


RESULTS
The higher order aberrations were detected in all the eyes (100%) of Group 1-3. The higher order aberration of Group 1 (the first week of post-operation) was RMSh (0.3774 +/- 0.2311) microm, which of Group 2 (the first month of post-operation) was RMSh (0.4782 +/- 0.395 2) microm, which of Group 3 (the third month of post-operation) was RMSh (0.2880 +/- 0.1522) microm. The higher order aberration of the control group was RMSh (0.3412 +/- 0.2048) microm. The difference of higher order aberration root mean square (RMSh) values between Group 3 and Group 2 has statistical significance (P < 0.05). But the differences of RMsh between the control group and Group 1, 2, 3 apart were no significant (P > 0.05).


CONCLUSIONS
The higher order aberrations of pseudophakic eyes may be a reason why the visual qualities of phakic eyes are not better than those of normal human eyes statistically when their vision acuity is alike. The IOLs which can reduce higher order aberrations will improve the visual qualities of pseudophakic eyes. Ophthalmologists are looking forward to optimizing and designing individual intraocular lens.
Li
Jianjing
J
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China.
Lin
Zhende
Z
Li
Yonghua
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002386:Cataract / Q000628:therapy*; D005260:Female; D006801:Humans; D007910:Lenses, Intraocular; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D016896:Treatment Outcome; D014792:Visual Acuity